Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX31VA
|
|||
| Drug Name |
PF-07248144
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1 | [1] | |
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone acetyltransferase KAT6A (KAT6A) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04606446) A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Pfzer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.